KR20090037242A - L-오르니틴-l-아스파테이트를 함유한 겔제의 제조방법 및그 겔제 - Google Patents
L-오르니틴-l-아스파테이트를 함유한 겔제의 제조방법 및그 겔제 Download PDFInfo
- Publication number
- KR20090037242A KR20090037242A KR1020070102795A KR20070102795A KR20090037242A KR 20090037242 A KR20090037242 A KR 20090037242A KR 1020070102795 A KR1020070102795 A KR 1020070102795A KR 20070102795 A KR20070102795 A KR 20070102795A KR 20090037242 A KR20090037242 A KR 20090037242A
- Authority
- KR
- South Korea
- Prior art keywords
- parts
- weight
- ornithine
- aspartate
- gel
- Prior art date
Links
- IXUZXIMQZIMPSQ-ZBRNBAAYSA-N [(4s)-4-amino-4-carboxybutyl]azanium;(2s)-2-amino-4-hydroxy-4-oxobutanoate Chemical compound OC(=O)[C@@H](N)CCC[NH3+].[O-]C(=O)[C@@H](N)CC(O)=O IXUZXIMQZIMPSQ-ZBRNBAAYSA-N 0.000 title claims abstract description 79
- 108010049063 ornithylaspartate Proteins 0.000 title claims abstract description 79
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 50
- 229930006000 Sucrose Natural products 0.000 claims abstract description 33
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims abstract description 33
- 239000005720 sucrose Substances 0.000 claims abstract description 33
- 238000000034 method Methods 0.000 claims abstract description 29
- 239000000203 mixture Substances 0.000 claims abstract description 24
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims abstract description 18
- 239000001768 carboxy methyl cellulose Substances 0.000 claims abstract description 15
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims abstract description 14
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims abstract description 14
- 239000000872 buffer Substances 0.000 claims abstract description 12
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 8
- 238000002156 mixing Methods 0.000 claims abstract description 7
- 230000008569 process Effects 0.000 claims abstract description 7
- 239000004480 active ingredient Substances 0.000 claims description 21
- 239000003755 preservative agent Substances 0.000 claims description 13
- 239000003086 colorant Substances 0.000 claims description 12
- 230000002335 preservative effect Effects 0.000 claims description 12
- 239000000796 flavoring agent Substances 0.000 claims description 10
- 235000013355 food flavoring agent Nutrition 0.000 claims description 10
- 235000003599 food sweetener Nutrition 0.000 claims description 9
- 239000003765 sweetening agent Substances 0.000 claims description 9
- 238000001914 filtration Methods 0.000 claims description 6
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 claims description 4
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 claims description 4
- 208000019423 liver disease Diseases 0.000 abstract description 5
- 230000003252 repetitive effect Effects 0.000 abstract description 2
- 238000002360 preparation method Methods 0.000 description 20
- 239000007864 aqueous solution Substances 0.000 description 12
- 239000008213 purified water Substances 0.000 description 10
- 238000012360 testing method Methods 0.000 description 7
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 5
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 5
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 5
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 5
- 229960003104 ornithine Drugs 0.000 description 5
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 4
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 4
- 229940069338 potassium sorbate Drugs 0.000 description 4
- 235000010241 potassium sorbate Nutrition 0.000 description 4
- 239000004302 potassium sorbate Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 235000002906 tartaric acid Nutrition 0.000 description 4
- 239000011975 tartaric acid Substances 0.000 description 4
- UJMBCXLDXJUMFB-UHFFFAOYSA-K trisodium;5-oxo-1-(4-sulfonatophenyl)-4-[(4-sulfonatophenyl)diazenyl]-4h-pyrazole-3-carboxylate Chemical group [Na+].[Na+].[Na+].[O-]C(=O)C1=NN(C=2C=CC(=CC=2)S([O-])(=O)=O)C(=O)C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 UJMBCXLDXJUMFB-UHFFFAOYSA-K 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 235000003704 aspartic acid Nutrition 0.000 description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 208000007386 hepatic encephalopathy Diseases 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 108010011485 Aspartame Proteins 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- 239000000605 aspartame Substances 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical group OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- 229960003438 aspartame Drugs 0.000 description 2
- 235000010357 aspartame Nutrition 0.000 description 2
- 229940009098 aspartate Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000001668 nucleic acid synthesis Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- IHCCLXNEEPMSIO-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 IHCCLXNEEPMSIO-UHFFFAOYSA-N 0.000 description 1
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 241000989913 Gunnera petaloidea Species 0.000 description 1
- 206010020575 Hyperammonaemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229960005261 aspartic acid Drugs 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- 230000004143 urea cycle Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
연령 | 10~19 | 20~29 | 30~39 | 40~49 | 50~59 | 60~69 |
인원수 | 3 | 6 | 8 | 15 | 11 | 7 |
기호도 | 하하 | 하중 | 하상 | 중하 | 중중 | 중상 | 상하 | 상중 | 상상 |
실시예 1 | 1 | 5 | 14 | 16 | 11 | 3 | |||
실시예 2 | 2 | 5 | 8 | 18 | 10 | 7 | |||
실시예 3 | 3 | 10 | 13 | 17 | 5 | 2 | |||
실시예 4 | 3 | 6 | 13 | 19 | 9 |
Claims (17)
- (A) L-오르니틴-L-아스파테이트 100 중량부를 기준으로, 보존제 0.4 내지 0.6 중량부 및 완충제 1.0 내지 1.6 중량부를 물 57 내지 87 중량부에 용해시키는 단계;(B) L-오르니틴-L-아스파테이트 100 중량부를 물 110 내지 176 중량부에 용해시킨 후 상기 단계 (A)의 혼합물에 용해시키는 단계; 및(C) 수크로스 12 내지 20 중량부 및 카르복시메틸셀룰로스나트륨 5.4 내지 8.5 중량부를 혼합한 후 상기 단계 (B)의 혼합물에 용해시키는 단계를 포함하는 것을 특징으로 하는 L-오르니틴-L-아스파테이트를 유효성분으로 함유하는 겔제의 제조방법.
- 청구항 1에 있어서, 상기 단계 (B)는2 내지 5 부분으로 분할된 상기 L-오르니틴-L-아스파테이트를 상기 L-오르니틴-L-아스파테이트의 분할비율과 동일한 비율로 분할된 상기 물에 각각 용해시킨 후, 상기 단계 (A)의 혼합물에 용해시키는 것을 특징으로 하는 L-오르니틴-L-아스파테이트를 유효성분으로 함유하는 겔제의 제조방법.
- 청구항 1에 있어서, 상기 단계 (C)는2 내지 5 부분으로 분할된 상기 수크로스 및 카르복시메틸셀룰로스나트륨을, 각각 혼합한 후, 순차적으로 상기 단계 (B)의 혼합물에 용해시키는 것을 특징으로 하는 L-오르니틴-L-아스파테이트를 유효성분으로 함유하는 겔제의 제조방법.
- 청구항 1에 있어서,상기 단계 (A)에 감미제 1.6 내지 2.4 중량부를 추가로 포함시키는 것을 특징으로 하는 L-오르니틴-L-아스파테이트를 유효성분으로 함유하는 겔제의 제조방법.
- 청구항 1에 있어서, 상기 단계 (A) 이후 단계 (B) 이전에,수크로스 10 내지 30 중량부를 상기 단계 (A)의 혼합물에 추가로 용해시키는 것을 특징으로 하는 L-오르니틴-L-아스파테이트를 유효성분으로 함유하는 겔제의 제조방법.
- 청구항 5에 있어서,상기 추가로 용해된 수크로스와 별도로, 일체로 또는 2 내지 4 부분으로 분할된 수크로스 30 내지 50 중량부를 상기 수크로스의 분할비율과 동일한 비율로 분할된 물 55 내지 88 중량부에 각각 용해시킨 후 추가로 첨가하는 것을 특징으로 하는 L-오르니틴-L-아스파테이트를 유효성분으로 함유하는 겔제의 제조방법.
- 청구항 1에 있어서, 상기 단계 (B) 이후 단계 (C) 이전에,착색제 0.08 내지 0.12 중량부를 물 6 내지 10 중량부에 용해시킨 후 상기 단계 (B)의 혼합물에 용해시키는 단계를 추가로 포함하는 것을 특징으로 하는 L-오르니틴-L-아스파테이트를 유효성분으로 함유하는 겔제의 제조방법.
- 청구항 1에 있어서, 상기 단계 (C) 이후에,착향제 5.5 내지 8.7 중량부를 상기 단계 (C)의 혼합물에 용해시키는 단계를 추가로 포함하는 것을 특징으로 하는 L-오르니틴-L-아스파테이트를 유효성분으로 함유하는 겔제의 제조방법.
- 청구항 1에 있어서, 상기 단계 (B) 이후 단계 (C) 이전에,물 7.5 내지 11.5 중량부를 상기 단계 (B)의 혼합물에 첨가하는 것을 특징으로 하는 L-오르니틴-L-아스파테이트를 유효성분으로 함유하는 겔제의 제조방법.
- 청구항 1에 있어서, 상기 단계 (C) 이후에,물 11 내지 17 중량부를 상기 단계 (C)의 혼합물에 첨가하는 것을 특징으로 하는 L-오르니틴-L-아스파테이트를 유효성분으로 함유하는 겔제의 제조방법.
- 청구항 1 내지 청구항 10 중 어느 한 청구항에 있어서,상기 물은 끓인 후 60 내지 80 ℃로 식힌 것을 특징으로 하는 L-오르니틴-L- 아스파테이트를 유효성분으로 함유하는 겔제의 제조방법.
- 청구항 1 내지 청구항 10 중 어느 한 청구항에 있어서,상기 단계 (A)의 혼합물, 상기 수크로스를 용해한 물, 또는 상기 L-오르니틴-L-아스파테이트를 용해한 물을 여과하는 단계를 추가로 포함하는 것을 특징으로 하는 L-오르니틴-L-아스파테이트를 유효성분으로 함유하는 겔제의 제조방법.
- 청구항 1 내지 청구항 10 중 어느 한 청구항에 의해 제조된 것을 특징으로 하는 L-오르니틴-L-아스파테이트를 유효성분으로 함유하는 겔제.
- L-오르니틴-L-아스파테이트 100 중량부;카르복시메틸셀룰로스나트륨 5.4 내지 8.5 중량부;보존제 0.4 내지 0.6 중량부;완충제 1.0 내지 1.6 중량부;수크로스 12 내지 20 중량부; 및물 250 내지 400 중량부를 포함하는 것을 특징으로 하는 L-오르니틴-L-아스파테이트를 유효성분으로 함유하는 겔제.
- 청구항 14에 있어서,수크로스 40 내지 60 중량부를 추가로 포함하는 것을 특징으로 하는 L-오르니틴-L-아스파테이트를 유효성분으로 함유하는 겔제.
- 청구항 14에 있어서,감미제 1.6 내지 2.4 중량부를 추가로 포함하는 것을 특징으로 하는 L-오르니틴-L-아스파테이트를 유효성분으로 함유하는 겔제.
- 청구항 14에 있어서,착색제 0.08 내지 0.12 중량부 및 착향제 5.5 내지 8.7 중량부를 추가로 포함하는 것을 특징으로 하는 L-오르니틴-L-아스파테이트를 유효성분으로 함유하는 겔제.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020070102795A KR100970664B1 (ko) | 2007-10-11 | 2007-10-11 | L-오르니틴-l-아스파테이트를 함유한 겔제의 제조방법 및그 겔제 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020070102795A KR100970664B1 (ko) | 2007-10-11 | 2007-10-11 | L-오르니틴-l-아스파테이트를 함유한 겔제의 제조방법 및그 겔제 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20090037242A true KR20090037242A (ko) | 2009-04-15 |
KR100970664B1 KR100970664B1 (ko) | 2010-07-15 |
Family
ID=40762026
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020070102795A KR100970664B1 (ko) | 2007-10-11 | 2007-10-11 | L-오르니틴-l-아스파테이트를 함유한 겔제의 제조방법 및그 겔제 |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100970664B1 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108226346A (zh) * | 2018-01-18 | 2018-06-29 | 朱路英 | 一种检测门冬氨酸鸟氨酸特定杂质的分析方法 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JOP20190146A1 (ar) | 2016-12-19 | 2019-06-18 | Axcella Health Inc | تركيبات حمض أميني وطرق لمعالجة أمراض الكبد |
CN111295187A (zh) | 2017-08-14 | 2020-06-16 | 胺细拉健康公司 | 用于治疗肝脏疾病的氨基酸组合物 |
EP3810123A1 (en) | 2018-06-20 | 2021-04-28 | Axcella Health Inc. | Compositions and methods for the treatment of fat infiltration in muscle |
CN112689504A (zh) | 2018-06-20 | 2021-04-20 | 胺细拉健康公司 | 含有苦味氨基酸的治疗和保健组合物 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04120063A (ja) * | 1990-09-07 | 1992-04-21 | Ishihara Sangyo Kaisha Ltd | イミダゾール系化合物の分離方法 |
-
2007
- 2007-10-11 KR KR1020070102795A patent/KR100970664B1/ko active IP Right Grant
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108226346A (zh) * | 2018-01-18 | 2018-06-29 | 朱路英 | 一种检测门冬氨酸鸟氨酸特定杂质的分析方法 |
Also Published As
Publication number | Publication date |
---|---|
KR100970664B1 (ko) | 2010-07-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100970664B1 (ko) | L-오르니틴-l-아스파테이트를 함유한 겔제의 제조방법 및그 겔제 | |
TWI583402B (zh) | 阿托莫西汀(atomoxetine)溶液 | |
JP2015522624A5 (ko) | ||
CN110151592B (zh) | 一种组合物及其制备方法和用途 | |
JP2012136492A (ja) | 服用感を改善された漢方内服液剤 | |
JP2015063497A (ja) | 経口用組成物 | |
JP2003231647A (ja) | 内服液組成物 | |
JP5419451B2 (ja) | 歯のエナメル質の溶解阻害剤 | |
JP5434981B2 (ja) | 点眼剤 | |
JP2000239173A (ja) | 鉄化合物含有内服液剤組成物 | |
JP3668483B2 (ja) | 生薬エキス配合液剤 | |
TWI316403B (en) | Glycyrrhizin containing pharmaceutical composition | |
JP4403595B2 (ja) | 鉄化合物含有内服液剤組成物 | |
JP4403587B2 (ja) | 低pHで安定な生薬エキス配合液剤 | |
JPH0698729A (ja) | 朝鮮人参エキス含有飲料とその製造方法 | |
JP2004315439A (ja) | 鉄化合物配合内服用液体組成物 | |
CN110151688A (zh) | 一种盐酸氨溴索注射液组合物及其制备方法 | |
KR102342514B1 (ko) | 글리세로인산마그네슘을 포함하는 경구투여용 수성 용액 형태의 약학 조성물 | |
CN105853473B (zh) | 一种奥拉西坦的药物组合物及其制备方法 | |
EP3678498B1 (en) | Composition for calcium supplementation | |
JPH0725769A (ja) | アロプリノール医薬用液剤ならびにその製造法 | |
JPH08198762A (ja) | 動物性生薬配合液剤 | |
KR101458670B1 (ko) | 분지쇄아미노산을 함유하는 약제학적 조성물 및 그 제조방법 | |
JP2000256186A (ja) | 咽頭疾患用組成物 | |
JP6578828B2 (ja) | 医薬品組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130617 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20140618 Year of fee payment: 5 |
|
J206 | Request for trial to confirm the scope of a patent right | ||
FPAY | Annual fee payment |
Payment date: 20150709 Year of fee payment: 6 |
|
J301 | Trial decision |
Free format text: TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20150417 Effective date: 20151023 |
|
FPAY | Annual fee payment |
Payment date: 20160711 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20180704 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20190710 Year of fee payment: 10 |